SOX2 and cancer: The SOX2+ SOCs contributed to therapy resistance to staurosporine, carboplatin, cisplatin and paclitaxel and disease relapse in the patients with ovarian cancer through induction of cancer stemness and apoptosis resistance (Bareiss et al., 2013).